The discovery of GCC expression as a unique biomarker for detecting metastatic colorectal cancer has led to the development of the GCC Cancer Vaccine and GCC CAR-T cell therapeutics.
Click below to learn more to read about the clinical trials for these potential breakthrough therapies.
| GCC Cancer Vaccine | GCC CAR-T |
|---|---|
| FDA phase I clinical trial complete; currently preparing for FDA phase IIa clinical trial | Preclinical trials completed; preparations for FDA phase I clinical trial are underway |
| Preclinical Study Phase I Trial Phase II Trial Design | Preclinical Study Phase I Trial |
